1Dent R, Trudeau M, Pritchard K I, et al. Triple- negative breast cancer: clinical features and patterns of recurrence [M]. Clin Cancer Res. United States, 2007: 4429.
2Rakha E A, El - Sayed M E, Green A R, et al. Prognostic markers in triple - negative breast cancer[J]. Cancer, 2007, 109 : 25.
3LiedtkeC, MazouniC, Hess KR, etal. Response toneoadjuvant therapy andlong- terrn survival in patients with triple -negative breast cancer[J]. J Clin Oncol, 2008, 26(8): 1275.
4Carey L A, Dees E C, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes[J]. Clin Cancer Res, 2007, 13(8) : 2329.
5Rouzier R, Perou C M, Symmans W F, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy[J]. Clin Cancer Res, 2005, 11(16): 5678.
6Rodenhuis S, Bontenbal M, van Hoesel Q G, et al. Efficacy of high- dose alkylating chemotherapy in HER2/neu- negative breast cancer[J]. Ann Oncol, 2006, 17(4) : 588.
7Gluz O, Nitz U A, Harbeck N, et al. Triple- negative high -risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM -01 trial[J]. Ann Oncol, 2008, 19(5): 861.
8Turner N, Tutt A, Ashworth A. Hallmarks of BRCAness' in sporadic eancers[J ]. Nat Rev Cancer, 2004, 4(10) : 814.
9Potemski P, Kusinska R, Watala C, et al. Prognostic relevance of basal cytokeratin expression in operable breast cancer [J]. Oncology, 2005, 69(6): 478.
10Nitz U A, Gluz O, Herr A, et al. Retrospective analysis of WSG AM01 tandem high dose chemotherapy trial in high risk primary breast cancer: A hypothesis generating study[M]. J Clin Oncol (Meeting Abstracts), 2006 : 665.
同被引文献22
1Perou CM,Sorlie T,Eisen MB,et al.Molecular portraits of human breast tumours. Nature . 2000
2Cleator S,Heller W,Coombes R C,et al.Triple-negative breast cancer: therapeutic options. Lancet Oncology,The . 2007
